Galmed Pharmaceuticals (GLMD) Total Non-Current Liabilities (2013 - 2024)

Galmed Pharmaceuticals' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $1.7 million for Q4 2024.

• In Q4 2024, Total Non-Current Liabilities rose 165.13% year-over-year to $1.7 million; the TTM figure through Dec 2024 stood at $1.7 million (up 165.13% YoY), while the FY2024 annual figure was $1.7 million, up 165.13% from the prior year.
• Total Non-Current Liabilities was $1.7 million for Q4 2024 at Galmed Pharmaceuticals, up from $628000.0 in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $216.0 million in Q4 2020 to a low of $44000.0 in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $15.0 million across 5 years, with a median of $274000.0 in 2021.
• The sharpest annual moves came in 2020 and 2021: Total Non-Current Liabilities surged 61263.64% in 2020, then tumbled 99.89% in 2021.
• A 5-year view of Total Non-Current Liabilities shows it stood at $216.0 million in 2020, then sank by 99.89% to $229000.0 in 2021, then plunged by 80.79% to $44000.0 in 2022, then soared by 1327.27% to $628000.0 in 2023, then jumped by 165.13% to $1.7 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $1.7 million (Q4 2024), $628000.0 (Q4 2023), and $5.1 million (Q1 2023), per Business Quant data.